Available from: Australian Government
[441] Lastly, in the Health Data, Technology, and Interoperability: Electronic Prescribing, Real-Time Prescription Benefit and Electronic Prior Authorization (HTI-4) final rule (90 FR 36541 and 36542), published as part of the FY 2026 IPPS/LTCH final rule, ASTP/ONC finalized a subset of new and revised standards and ONC health IT certification criteria proposed in the HTI-2 proposed rule for the ONC Health IT Certification Program, including the following policies: ASTP/ONC updated the electronic prescribing certification criterion in45 CFR 170.315(b)(3) to incorporate National Council for Prescription Drug Programs (NCPDP) SCRIPT standard version 2023011, require support for electronic prior authorization transactions in accordance with this standard, and revise other elements of the criterion
How It Works Activates both GLP-1 and GIP receptors for a broader metabolic impact Reduces appetite and increases satiety through two hormonal pathways Enhances insulin sensitivity more aggressively than GLP-1 alone Supports reduction of visceral fat the deep abdominal fat most strongly associated with metabolic disease Improves blood sugar regulation through a dual insulin-stimulating mechanism Clinical Results In the SURMOUNT-1 trial, Tirzepatide produced average weight loss of up to 20% of body weight outperforming Semaglutide in head-to-head comparisons
What Exactly Are These Inositols
This type progresses slowly, with new patches forming periodically on both sides of the body, often symmetrically, such as on both knees or hands
